World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
22941
World Ranking
17133
National Ranking
8583

Overview

David J. Straus is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with particular attention to pathology and forensic medicine, oncology, pulmonary and respiratory medicine, genetics, and neurology.

The scientist's work covers various specialized topics, including:

  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Cutaneous lymphoproliferative disorders research

David J. Straus has contributed to a significant number of publications in several well-known medical and oncology journals. The frequent publication venues include:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Recent papers authored or co-authored by Straus illustrate involvement in clinical trials and lymphoma studies. Notable publications include:

  • "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma," 2022, published in New England Journal of Medicine
  • "Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups," 2020, published in Blood Cancer Journal
  • "Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma," 2021, published in Journal of Clinical Oncology
  • "Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial," 2021, published in The Lancet Haematology

The scientist has collaborated frequently with several co-authors, reflecting a network of partnerships within the oncology research community. Frequent collaborators include Ariela Noy, Andrew D. Zelenetz, Matthew J. Matasar, Alison J. Moskowitz, and Steven M. Horwitz.

Best Publications

  • Molecular Basis of T Cell Inactivation by CTLA-4

    Kyung Mi Lee;Ellen Chuang;Matthew Griffin;Roli Khattri

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data

    Jeffrey J. Gaynor;Erick J. Feuer;Claire C. Tan;Danny H. Wu

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection

    Lawrence D. Kaplan;David J. Straus;Marcia A. Testa;Jamie Von Roenn

  • Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

    Craig H. Moskowitz;Heiko Schöder;Julie Teruya-Feldstein;Camelia Sima

  • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

    David J. Straus;Carol S. Portlock;Jing Qin;Jane Myers

  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

    Paul A. Hamlin;Andrew D. Zelenetz;Tarun Kewalramani;Jing Qin

  • Regulation of PAK Activation and the T Cell Cytoskeleton by the Linker Protein SLP-76

    Juliane Bubeck Wardenburg;Rajita Pappu;Jia-Ying Bu;Bruce Mayer

  • AIDS-related lymphoid neoplasia. The Memorial Hospital experience.

    Dennis A. Lowenthal;David J. Straus;Susanne Wise Campbell;Jonathan W. M. Gold

  • Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

    Lee Ratner;Jeannette Lee;Shenghui Tang;David Redden

  • Primary gastrointestinal lymphoma: A 30‐year review

    Daniel N. Weingrad;Jerome J. Decosse;Paul Sherlock;David Straus

  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

    Craig H. Moskowitz;Matt J. Matasar;Andrew D. Zelenetz;Stephen D. Nimer

  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

    Oliver W. Press;Oliver W. Press;Hongli Li;Heiko Schöder;David J. Straus

  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

    Alison J. Moskowitz;Heiko Schöder;Joachim Yahalom;Susan J. McCall

  • Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

    V A Miller;F M Benedetti;J R Rigas;A L Verret

  • Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.

    S C Gulati;B Shank;P Black;J Yopp

  • Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

    H. Miles Prince;Madeleine Duvic;Ann Martin;Wolfram Sterry

Frequent Co-Authors

Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Heiko Schöder
Heiko Schöder Memorial Sloan Kettering Cancer Center
Bayard D. Clarkson
Bayard D. Clarkson Memorial Sloan Kettering Cancer Center
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Miguel-Angel Perales
Miguel-Angel Perales Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s important to explore related online degrees and alternative career pathways within healthcare. Many students choose to pursue nursing or advanced practice options either as first steps or as rewarding careers of their own.

If cost and flexibility are your priorities, there are affordable nursing programs online that allow you to earn a nursing degree from home while balancing other commitments. For registered nurses seeking to expand their skills and improve job prospects, enrolling in affordable rn to bsn programs offers a streamlined path to a bachelor’s degree.

Those with a non-nursing background who wish to enter the nursing field quickly should consider direct entry online msn programs. These programs are designed for motivated individuals to earn a master’s degree efficiently.

Finally, experienced nurses looking to advance into leadership, education, or research roles can benefit from an online nursing doctorate. Whichever path you choose, online programs offer flexibility, affordability, and a wide range of career opportunities in healthcare.

Best Scientists Citing David J. Straus

Trending Scientists

Recently Published Articles